Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.5052W HIGH $15.37
Volume
91.32 K
Value Traded
574.59 K
Short % Float
7.25%
Days to Cover
14.3
-0.79%Week
-5.57%1 Month
-2.94%3 Month
-2.87%6 Month
+32.8%5 Year
+32.8%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
333.63 M
EPS (TTM)
-0.56
P/E Ratio
-
Ent. Value
311.87 M
Total Shares
53.21 M
Float Shares
26.90 M
Insiders
49.45%
Institutions
10.31%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
CV Catalyst Timeline
Dated clinical, regulatory and corporate events for CapsoVision, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for CapsoVision, Inc.
5Total events
1Upcoming
0Tier-1 (high impact)
2026 to 2027Coverage
Event history 1
Past FDA Catalysts and PDUFA Decisions
How CV actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
CapsoVision, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every CV program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| HARARI ELIYAHOU ET AL10% Owner | BuyOffering | 878,735 1,396,494 held | $5.69 | 09/18/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CV
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in CV for Q2 2026. | ||||
Ownership Trends
CV Short Interest
Shares sold short, counted twice a month.
7.25%
Short % of Float
of tradable shares sold short
2.0M
Shares Sold Short
-10.6% vs prior count
14.3 Very high
Days to Cover
trading days of normal volume to buy every short share back
136.2K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CV ranks across every disease it competes in
Competitive Position is a premium feature
See how CV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCV News
CV▼ -1.6%today
CapsoVision Reports Third Quarter 2026 Financial Results
CapsoVision reported a revenue increase to $3.6 million for Q3 2026, up from $3.5 million in Q3 2025. The company launched its AI Highlights tool, enhancing its CapsoCam Plus product. Despite a net loss of $7.3 million, CapsoVision is optimistic about future growth driven by new product offerings and clinical studies.
Read more →CVCapsoVision to Release Third Quarter 2026 Financial Results on November 12, 2026
CapsoVision, a medical technology company, will announce its third quarter 2026 financial results on November 12, 2026. A conference call will follow to discuss the results and provide updates. The company focuses on advanced imaging and AI-enabled solutions for gastrointestinal diseases.
Read more →CVCapsoVision to Present at the 20th Annual LD Micro Main Event
CapsoVision, Inc. will present at the 20th Annual LD Micro Main Event from October 19-21, 2026. Key executives, including CEO Johnny Wang, will discuss the company's advanced imaging and AI-enabled solutions for gastrointestinal diseases. The presentation is scheduled for October 21, 2026, and will be available via live webcast. The company aims to transform diagnostics with its innovative products.
Read more →CVCapsoVision Announces FDA Clearance of AI Highlights for CapsoCam Plus®
CapsoVision, Inc. announced that its AI Highlights tool for the CapsoCam Plus system received FDA clearance on September 25, 2026. This AI-assisted reading tool is designed to help physicians review small bowel capsule endoscopy studies more efficiently by highlighting suspected abnormal lesions. The tool integrates with CapsoView and CapsoCloud, enhancing workflows for healthcare professionals.
Read more →CVCapsoVision to Participate in Upcoming Investor Conferences
CapsoVision, Inc. will participate in two upcoming investor conferences, including the H.C. Wainwright 28th Annual Global Investment Conference and the 5th Annual ROTH Healthcare Opportunities Conference. The company will present on-demand and hold one-on-one meetings with investors. CapsoVision focuses on advanced imaging and AI-enabled solutions for gastrointestinal diseases.
Read more →CVCapsoVision Reports Second Quarter 2026 Financial Results
CapsoVision, Inc. reported a 10% revenue increase for Q2 2026, totaling $3.6 million. The company launched its AI Highlights™ feature internationally and anticipates FDA clearance by Q3 2026. Despite revenue growth, gross margins fell due to competitive pressures and increased operating expenses. The company continues to expand its product pipeline and customer base.
Read more →CVCapsoVision® Announces International Launch of AI Highlights
CapsoVision, Inc. has announced the international launch of AI Highlights, a feature for its CapsoCam Plus system designed to enhance the review process of small bowel capsule endoscopy studies. This AI-enabled tool identifies frames with clinically relevant findings, supporting physicians in their assessments. While the product is available in markets like the EU, it has not yet received FDA clearance for use in the U.S.
Read more →CVCapsoVision to Release Second Quarter 2026 Financial Results on August 13, 2026
CapsoVision, a medical technology company, will announce its second quarter 2026 financial results on August 13, 2026. Following the release, a conference call will be held to discuss the results and provide a corporate update. The company specializes in advanced imaging and AI-enabled capsule endoscopy solutions.
Read more →CV▼ -9.2%on this news· ran to -22% by day 1
CapsoVision Appoints Gastroenterology Leader David S. Shields, M.D., to Board of Directors
CapsoVision, Inc. has appointed Dr. David S. Shields to its Board of Directors, effective July 1, 2026. Dr. Shields, a board-certified gastroenterologist with over 40 years of experience, succeeds Dr. Joanne C. Imperial, who will continue as a clinical consultant. The company is poised for growth with upcoming product launches and advancements in AI-enabled capsule endoscopy technology.
Read more →CVCapsoVision Reports First Quarter 2026 Financial Results
CapsoVision, Inc. reported its first quarter 2026 financial results, maintaining revenue at $2.8 million. The company noted increased clinical use of its CapsoCam Plus product and secured key customer renewals. However, gross profit decreased by 11%, and operating expenses rose due to ongoing development efforts. The anticipated FDA clearance for its AI-assisted reading feature is expected mid-year.
Read more →CV▲ +10.6%on this news
CapsoVision to Release First Quarter 2026 Financial Results on May 14, 2026
CapsoVision, Inc. will announce its first quarter 2026 financial results on May 14, 2026. A conference call and webcast will follow the results release, allowing for investor engagement. The company focuses on advanced imaging and AI solutions for gastrointestinal diagnostics, with notable products in its pipeline.
Read more →CV▼ -8.9%on this newsshared move
CapsoVision Reports Fourth Quarter and Full Year 2025 Financial Results
CapsoVision, Inc. reported strong financial results for Q4 and full year 2025, with revenues rising 15% year-over-year. The company expanded its customer base and submitted a 510(k) application for an AI module to the FDA. However, operating expenses increased due to product development and clinical trials. The company remains focused on advancing its technology and product pipeline.
Read more →CV▲ +11.2%on this news· ran to +34% by day 3
CapsoVision Announces $14 Million Private Placement Financing
CapsoVision, Inc. has successfully closed a $14 million private placement to accredited investors, selling 2,867,089 shares at a 5% discount. The funds will be used for corporate purposes, including R&D and marketing. The company also announced preliminary financial results for 2025, with revenues of $3.9 million in Q4 and $13.6 million for the full year.
Read more →CVCapsoVision to Release Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 26, 2026
CapsoVision, Inc. will announce its fourth quarter and full year 2025 financial results on March 26, 2026. A conference call will follow the release to discuss the results and provide updates. The company focuses on advanced imaging and AI-enabled solutions for gastrointestinal diseases, with products like CapsoCam Plus® and the upcoming CapsoCam Colon™.
Read more →CV▼ -11%on this news· ran to -21% by day 3
CapsoVision Announces 510(k) Submission for the Addition of AI-Assisted Reading Module in CapsoCam Plus Company Preparing to Commence Commercialization Following U.S. FDA 510(k) Clearance
CapsoVision, Inc. has announced the submission of its 510(k) application to the FDA for an AI-assisted reading module to enhance its CapsoCam Plus capsule endoscopy system. This development aims to improve the detection of significant pathologies and decrease clinician review time. Following FDA clearance, CapsoVision plans to initiate commercialization efforts. The company positions itself as a leader in the capsule endoscopy space with its integrated imaging and AI technology.
Read more →CVCapsoVision Reports Third Quarter 2025 Financial Results
CapsoVision, Inc. reported third quarter 2025 financial results with revenues of $3.5 million, representing a 19% increase from the prior year. The company welcomed significant growth in new accounts and a substantial user base for its CapsoCam Plus product. Additionally, it submitted an application for Breakthrough Device Designation to expedite the development of an endoscopy capsule aimed at early-stage pancreatic cancer detection. Despite increases in operating expenses and a modest decline in gross margin, CapsoVision highlighted its commitment to advancing healthcare technology through strategic partnerships and innovations.
Read more →CVCapsoVision Submits Breakthrough Device Designation Application to FDA for Pancreatic Cancer Screening Capsule
CapsoVision has submitted an application to the FDA seeking Breakthrough Device Designation for its CapsoCam UGI capsule endoscopy system aimed at early-stage pancreatic cancer detection. This innovative device offers a non-invasive method for screening a disease known for its high mortality rate due to late-stage diagnosis. The Breakthrough Devices Program could expedite its development and regulatory review process. However, the company faces potential hurdles, including meeting FDA eligibility requirements for the designation and obtaining marketing authorization.
Read more →CVCapsoVision Appoints David Garcia as Senior Vice President of Finance Seasoned finance executive brings public company, capital markets and transaction experience to support next phase of growth
CapsoVision, a medical technology company, has appointed David Garcia as Senior Vice President of Finance, effective November 3, 2025. Garcia brings over 20 years of financial leadership experience, including roles at Matterport, Inc., where he played a key part in the company's IPO. His expertise is expected to support CapsoVision's growth strategy and development pipeline, particularly in advanced imaging and AI-enabled capsule endoscopy solutions. The company aims to transform the detection of gastrointestinal diseases through innovative technology.
Read more →CVCapsoVision Reports Second Quarter 2025 Financial Results
CapsoVision, Inc. reported a 17% rise in revenue for Q2 2025, totaling $3.3 million, alongside a 75% growth in new accounts. The company also completed a successful IPO, raising approximately $23.4 million to support expansion into new indications. While management remains optimistic about future growth through additional product enhancements and regulatory approvals, the financial report highlighted a $4.6 million operating loss and a significant decline in cash reserves, raising concerns about sustainability.
Read more →CVCapsoVision Announces Pricing of Initial Public Offering
CapsoVision, a commercial-stage medical technology company, has announced the pricing of its initial public offering (IPO) at $5.00 per share, totaling approximately $27.5 million in gross proceeds. Trading on the Nasdaq Capital Market is set to begin on July 2, 2025, under the ticker symbol CV. The company aims to utilize the funds to advance its innovative imaging technologies and expand its product pipeline targeting gastrointestinal diseases. The offering remains contingent upon standard closing conditions.
Read more →About CapsoVision, Inc.
Headquarters18805 COX AVENUE SUITE 250, SARATOGA, CA, 95070
BIOPHARMAWATCH ELITE
Trade the next CV catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime